Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT
Announcement on the Progress of Share Repurchase

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**" or "**GenFleet**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to (i) the notice (the "**Notice**") of the annual general meeting (the "**AGM**") and the circular (the "**Circular**") of the Company dated April 17, 2026; (ii) the resolution passed by the Shareholders at the AGM held on May 11, 2026, in which the board of directors of the Company (the "**Board**") was granted a general mandate (the "**Repurchase Mandate**") to repurchase H shares of the Company (the "**H Shares**"); (iii) the Company's voluntary announcement on its proposal of share repurchase dated June 29, 2026 (the "**Announcement**"). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular, the Repurchase Mandate and the Announcement.

As of November 6, 2026, the Company made a series of repurchases of its H Shares on The Stock Exchange of Hong Kong Limited, totaling an aggregate of 2,907,800 H Shares (the "**Share Repurchase**"), which represents approximately 0.757% of the total number of issued Shares as of the date of this announcement.

The Company may continue to implement its 2026 H Shares repurchase plan as per assessment of the market conditions.

Shareholders and potential investors should note that the Share Repurchase will be subject to market conditions and will be made at the sole discretion of the Board. There is no assurance as to the timing, quantity or price of any Share Repurchase. Therefore, Shareholders and potential investors are advised to exercise caution when dealing in the H Shares.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, November 9, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive Directors; (ii) Mr. ZHU Jingyang as non-executive Director; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive Directors.